Using a ctDNA liquid biopsy assay for post-surgical serial monitoring and early detection of disease progression in advanced colorectal cancer patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F19%3AN0000131" target="_blank" >RIV/00064190:_____/19:N0000131 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1158/1538-7445.AM2019-405" target="_blank" >http://dx.doi.org/10.1158/1538-7445.AM2019-405</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1158/1538-7445.AM2019-405" target="_blank" >10.1158/1538-7445.AM2019-405</a>
Alternative languages
Result language
angličtina
Original language name
Using a ctDNA liquid biopsy assay for post-surgical serial monitoring and early detection of disease progression in advanced colorectal cancer patients
Original language description
Introduction: ctDNA liquid biopsy has been recognized as a useful approach to monitor effect of ongoing cancer treatment. The ctDNA dynamics is reflecting the overall tumor burden. Here we present a utility of a simple ctDNA assay for longitudinal monitoring of patients with advanced stages of colorectal cancer in conjunction with surgical treatment. Patients and Methods: In a prospective setting the disease course of a total of 121 patients in Stage III and IV of colorectal cancer was monitored by ctDNA. A panel of somatic mutations was initially screened in primary and/or metastatic tissue. The found mutations were then traced in ctDNA from plasma acquired before surgery and during the subsequent days and months. In a subgroup of rectal cancers ctDNA was also analyzed prior and during the neoadjuvant chemoradiotherapy. The ctDNA levels were then correlated to the clinical parameters such as surgical radicality, disease relapse or response to anticancer therapy.
Czech name
—
Czech description
—
Classification
Type
D - Article in proceedings
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/NV15-27939A" target="_blank" >NV15-27939A: Benefit of new "liquid biopsy" technology for monitoring of complex treatment of colorectal carcinoma in stage 3 and 4.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Article name in the collection
Proceedings: AACR Annual Meeting 2019
ISBN
—
ISSN
0008-5472
e-ISSN
—
Number of pages
2
Pages from-to
Abstract 405
Publisher name
American Association for Cancer Research
Place of publication
Atlanta
Event location
Atlanta
Event date
Mar 29, 2019
Type of event by nationality
WRD - Celosvětová akce
UT code for WoS article
—